FLX475 in Combination With Ipilimumab in Advanced Melanoma

Summary

This clinical trial is a Phase 2, open-label study to determine the anti-tumor activity of FLX475 in combination with ipilimumab in subjects with advanced melanoma previously treated with an anti-programmed cell death 1 (anti-PD-1) or anti-programmed cell death ligand 1 (anti-PD-L1) agent. The study will be conducted starting with a safety run-in portion in which 6 eligible subjects will be enrolled and treated for at least one 3-week cycle to determine if the safety profile of FLX475+ipilimumab is acceptable to complete enrollment of the approximately 20-subject study.

Timeline

Start

2021-09-03

Primary completion

2022-09-13

Completion

2022-09-13

Outcome

Outcome not reported

Stopped: “Change in clinical landscape”

Drugs

Indications